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Abstract 
Background: Selenium (Se) is an essential micronutrient trace element and an established nutritional antioxidant. 
Low Se status exacerbates inflammatory bowel diseases progression, which involves hyper inflammation in the diges-
tive tract. Se nanoparticles (SeNPs) exhibit anti-inflammatory activity accompanied by low toxicity, especially when 
decorated with natural biological compounds. Herein, we explored the beneficial effects of SeNPs decorated with 
Ulva lactuca polysaccharide (ULP) in mice subjected to the acute colitis model.
Results: We constructed SeNPs coated with ULP (ULP-SeNPs) in average diameter ~130 nm and demonstrated their 
stability and homogeneity. Supplementation with ULP-SeNPs (0.8 ppm Se) resulted in a significant protective effect 
on DSS-induced acute colitis in mice including mitigation of body weight loss, and colonic inflammatory damage. 
ULP-SeNPs ameliorated macrophage infiltration as evidenced by decreased CD68 levels in colon tissue sections. The 
anti-inflammatory effects of ULP-SeNPs were found to involve modulation of cytokines including IL-6 and TNF-α. 
Mechanistically, ULP-SeNPs inhibited the activation of macrophages by suppressing the nuclear translocation of 
NF-κB, which drives the transcription of these pro-inflammatory cytokines.
Conclusions: ULP-SeNPs supplementation may offer therapeutic potential for reducing the symptoms of acute coli-
tis through its anti-inflammatory actions.
Keywords: Selenium (Se), Selenium nanoparticles (SeNPs), Ulva lactuca polysaccharide (ULP), Inflammatory bowel 
diseases (IBD), Nuclear factor κ-B (NF-κB)
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Background
The micronutrient trace element selenium (Se) is an 
established nutritional antioxidant. Se carries out its bio-
logical effects mainly through the 21st amino acid, sele-
nocysteine, which is incorporated into selenoproteins [1]. 
Se deficiency has been demonstrated in association with 
increased risk of chronic inflammatory diseases such as 
cardiovascular disease and inflammatory bowel diseases 
(IBD) [2]. IBD is characterized by hyper inflamma-
tory conditions of the colon and small intestine includ-
ing Crohn’s disease (CD) and ulcerative colitis (UC). 
Decreased levels of Se have been observed in both UC 
and CD patients [3]. Moreover, low Se status was found 
to be associated with exacerbated CD severity and colon 
cancer risk with an involvement of enhanced epithelial 
injury [4, 5]. Selenoproteins play important roles in the 
pathophysiological processes of fine-tuning immunity 
and inflammatory responses [1]. However, beneficial 
effects of many other types of dietary and supplemental 
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SeNPs appear to be more effective than that of other 
forms of Se at increasing selenoproteins expression, 
scavenging free radicals, and preventing oxidative DNA 
damage and have additional benefits such as low toxic-
ity and acceptable bioavailability [6, 7]. Investigations in 
nanomedicine have shown that nanoparticles decorated 
with natural biological compounds exhibited therapeutic 
potential with low adverse effects through specific inter-
actions with target cells [8, 9]. Several strategies to direct 
nanoparticles into the gut mucosa for treatment of IBD 
have also been documented, mainly for local (rectal) use 
[10, 11]. A recent study investigated how drug loaded 
polymeric nanoparticles targeted the site of inflamma-
tion and analyzed the influence of different colon-specific 
delivery strategies [12]. We have found that some capping 
agents such as ATP and vitamin C on SeNPs can not only 
control the size and stability of SeNPs but also enhance 
cellular uptake and prolong circulation of SeNPs [13]. 
These effects are apparent despite the similar physical 
and chemical properties of decorated and undecorated 
SeNPs compounds and equivalent Se bioavailability [14].
Polysaccharides possess various pharmacological 
activities, including immune regulation, anti-oxidation, 
antiviral activities, anti-oncological activity, anti-coag-
ulation, and anti-aging effects. Mounting evidence sug-
gests that fabrication of nanomaterials with bioactive 
polysaccharide may have several advantages [15, 16]. 
Ulva lactuca polysaccharide (ULP) displays several phys-
icochemical and biological features of interest for food, 
pharmaceutical, agricultural, and chemical applications. 
Previous studies have shown that ULP had potent effects 
on cholesterol lowering, immunomodulatory and anti-
heptotoxic property in  vivo and in  vitro [17, 18]. ULP 
consisting of rhamnose, xylose, glucose, uronic acid, 
and sulfate was shown to stabilize the functional status 
of bio-membranes and act as an antioxidant and sur-
factant [18–20]. Accordingly, we set out to design SeNPs 
decorated with ULP and hypothesized that these SeNPs 
would exhibit anti-inflammatory activity accompanied by 
low toxicity for functionally attenuating IBD.
In the present study, we constructed ULP-SeNPs of an 
average diameter ~130  nm. We explored the therapeu-
tic effects of ULP-SeNPs on mice subjected to the DSS-
induced colitis mouse model. We also investigated the 
function of ULP-SeNPs in inhibiting NF-κB activation in 
macrophages, which represents an important mechanism 




Nanoparticles with size ranging from 30 to 150 nm were 
produced to enhance the cellular uptake, with both size 
and stability being important [21, 22]. Size-controlled 
SeNPs were prepared in the redox reaction system of sel-
enite acid and ascorbic acid, and for some of these parti-
cles we added ULP to generate ULP-SeNPs. The particle 
size, stability and dispersity of SeNPs and ULP-SeNPs 
were measured as shown in Fig.  1. SeNPs without ULP 
decoration showed an average diameter of 680 nm, while 
addition of 0.32 mg/mL ULP generated ULP-SeNPs with 
significantly decreased particle diameters to 131  nm 
(Fig. 1a). The particle-size distribution was 305–900 nm 
and 58–205 nm for SeNPs and SeNPs-ULP (0.32 mg/mL 
ULP), respectively (Fig.  1b). There was a trend toward 
an increase in size of SeNPs with adding ULP above the 
level of 0.32 mg/mL, which implied that the particle size 
of SeNPs has something to do with the concentrations 
of ULP. It was also found that the ULP-SeNPs remained 
stable at least for 60  days when stored in 0.32  mg/mL 
ULP solutions (Fig.  1c). Moreover, the TEM images of 
these nanoparticles clearly revealed that SeNPs tended 
to aggregate and precipitate in absence of ULP (Fig. 1d), 
while SeNPs decorated with 0.32 mg/mL ULP appeared 
to monodisperse into homogeneous spherical struc-
tures with an average diameter of 130 nm (Fig. 1e). The 
diagram from surface elemental composition analysis 
of ULP-SeNPs by EDX showed four signals, including a 
strong Se atom signal (78.4%) from SeNPs and minor sig-
nals of C (15.6%), O (4.4) and S (1.6%) that likely origi-
nated from the ULP (Fig. 1f ).
To monitor the physical characteristics of the ULP-
SeNPs in solution, we examined the stability of ULP-
SeNPs in mouse plasma and in digestion fluid after 
incubation for 24 h. The average size of ULP-SeNPs was 
maintained at ~130  nm in both plasma and digestion 
fluid indicating no aggregation of ULP-SeNPs (Additional 
file 1: Figure S1A, B). After centrifugation to remove the 
ULP-SeNPs, dissolved Se levels were only slightly altered 
in plasma, and Se levels increased by ~16% in the diges-
tion fluid in comparison with controls (Additional file 1: 
Figure S1C, D). These data imply that the ULP-SeNPs can 
be deconstructed to some extent in the digestive tract, 
which is consistent with data below showing increased 
Se levels in colon and liver of mice supplementated with 
ULP-SeNPs. To compare the cellular uptake of ULP-
SeNPs and SeNPs, intracellular Se concentrations were 
detected by ICP-MS after BMDMs were incubated with 
SeNPs or ULP-SeNPs for 24 h. Data showed that incuba-
tion of BMDMs with ULP-SeNPs (0.5  μM) significantly 
increased the intracellular Se concentration from 0.36 to 
16.25 ng/107 cells, which was ~2.4 times higher than that 
of SeNPs treatment (6.9  ng/107cells) (Additional file  1: 
Figure S2). Taken together, these results indicated that 
capping ULP on SeNPs not only controls the size and sta-
bility of SeNPs but also enhances cellular uptake.
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Effects of ULP‑SeNPs on the development of DSS‑induced 
colitis in mice
We first explored how ULP-SeNPs influenced inflam-
mation using the mouse model of DSS-induced colitis 
according to the procedure shown in Fig.  2a. In acute 
colitis, the mice treated with 0.8  ppm of ULP-SeNPs 
subjected to colitis (DSS + ULP-SeNPs) exhibited lower 
body weight (BW) loss, disease activity index (DAI) 
scores, and colon length (CL) changes compared with 
those of the DSS group (Fig.  2b–e). In the absence of 
colitis, administration of ULP-SeNPs to mice induced 
slight increases in BW and no other general effects on 
the animal’s health compared to untreated mice. These 
results suggest that ULP-SeNPs are capable of prevent-
ing the clinical manifestations of DSS-induced colitis. 
Accordingly, the following experiments only included 
groups of untreated negative controls (NC), DSS, and 
DSS + ULP-SeNPs.
Effect of ULP‑SeNPs on the colonic damage in DSS‑treated 
mice
To investigate the effects of ULP-SeNPs on colonic 
pathological changes during colitis, we examined colon 
tissue sections by H&E staining. The NC group had 
normal glands, abundant goblet cells in epithelium, 
no mucosal hyperplasia, and limited levels of infiltrat-
ing immune cells (Fig.  3a). In contrast, the DSS-treated 
group displayed severe histological damage and inflam-
matory responses, including disruption of epithelial cells, 
muscle layer thickness, loss of goblet cells and infiltration 
of inflammatory cells in the colon tissues (Fig. 3b). Com-
pared to the DSS-treated group, the ULP-SeNPs group 
exhibited decreases in the levels of histological altera-
tions and inflammatory cellular infiltration along with 
a milder loss of epithelial cells and less expansion of the 
lesion area in the colon tissues (Fig. 3c). In a manner con-
sistent with the pathological changes, ULP-SeNPs treat-
ment significantly reduced the total histological score of 
the colitis colon tissues (Fig. 3d).
Effects of ULP‑SeNPs on immune cell infiltration into colon 
tissue during colitis
DSS-induced colitis is characterized by substantial 
immune cell infiltration into colon tissue and myeloper-
oxidase (MPO) is a biomarker for neutrophil or monocyte/
macrophage infiltration [23]. We measured MPO activ-
ity in colon tissues of mice with DSS-induced colitis and 
found the DSS group exhibited high MPO activity (Fig. 5a). 
The ULP-SeNPs group showed a reduction in MPO activ-
ity compared with the DSS group (Fig.  5a). Next, in the 
colon we determined CD68 expression, which is a spe-
cific marker for monocytes/macrophages [24]. The DSS 
group showed high CD68 expression in lamina propria 








Fig. 1 Preparation and characterization of ULP-SeNPs. a Particle size of ULP-SeNPs prepared in absence and presence of ULP are shown at indicated 
concentrations of ULP. b Size distribution of SeNPs and ULP-SeNPs. c Stability of ULP-SeNPs particle size within the indicated time course, repre-
sentative TEM images of SeNPs (d) and ULP-SeNPs (e). f Representative EDX analysis of ULP-SeNPs. ULP-SeNPs were obtained at a concentration of 
0.32 mg/mL ULP after reacting for 24 h at room temperature in the dark
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expression in colon tissues (Fig. 4b, c). These data suggest 
that ULP-SeNPs inhibit immune cell infiltration in colon 
tissues during the progression of DSS-induced colitis.
Effects of ULP‑SeNPs on MDA, GSH, GPx and Se levels 
in DSS‑induced colitis
To investigate whether ULP-SeNPs affect oxidative stress, 
we measured MDA and GSH in the colon tissues of DSS-
treated mice with or without ULP-SeNPs. Data showed 
that DSS significantly increased the colonic MDA levels 
(3.55 ± 0.21 nmol/mg protein) compared with that of the 
NC group (0.67 ±  0.20 nmol/mg protein) (Fig. 5b). The 
ULP-SeNPs group showed significantly reduced colonic 
MDA levels of 1.84 ± 0.09 nmol/mg protein at 0.8 ppm 
ULP-SeNPs compared to DSS group (Fig.  5b). In addi-
tion, ULP-SeNPs also attenuated the DSS-induced reduc-
tion in colonic GSH levels in the colitis mice (Fig.  5c). 
We next measured total colonic glutathione peroxidase 
(GPx) activity to determine the selenoenzyme expression 
level during colitis DSS lowered GPx activity, but ULP-
SeNPs supplementation could reverse this effect (Fig. 5d). 
Specifically, the colonic Se levels of the ULP-SeNPs group 
was significantly higher than that of the DSS group 
(521.09 ± 18.06 vs 177.79 ± 6.38 ng/g), and even slightly 
higher than that of the NC group (506.06 ± 12.85 ng/g) 
(Fig.  5e). ULP-SeNPs supplementation also increased 
liver Se levels in comparison with DSS group (Fig.  5f ), 
implying ULP-SeNPs ameliorated some of the declines in 
Se status found during DSS induced colitis.
ULP‑SeNPs affect the expression of inflammatory markers 
in DSS‑treated mice
Production of pro-inflammatory cytokines is induced by 
the infiltration of mononuclear cells into the colon dur-
ing IBD, which contributes to the pathology. The anti-
inflammatory effects of ULP-SeNPs were investigated by 
measuring the inflammatory cytokines in plasma. Com-
pared to NC mice, the levels of inflammatory cytokines 
in plasma including IL-6 and TNF-α was increased in 
DSS-treated mice but this effect was mitigated by admin-
istration of ULP-SeNPs (Fig. 6a). In addition, we investi-
gated the effects of ULP-SeNPs on mRNA levels for the 
inflammatory cytokines and on iNOS and COX-2. DSS 
treatment remarkably increased mRNA levels for TNF-α 
and IL-6 compared to the NC group, whereas these 
effects were attenuated by ULP-SeNPs (Fig.  6b, c). Fur-
thermore, the ULP-SeNPs group showed lower COX-2 
and iNOS compared to the DSS group (Fig. 6d).
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Fig. 2 Effects of ULP-SeNPs on DSS-induced mouse colitis. a Experimental time lines for acute colitis mouse models induced by DSS with or with-
out ULP-SeNPs, and included negative controls with or without ULP-SeNPs. Groups were compared for body weight changes (b), DAI scores (c), and 
colon lengths (d), which were measured on day 11 after treatments. Data are mean ± SD (n = 10 mice per group). *P < 0.05; **P < 0.01; ***P < 0.001 
(significantly different from the DSS group). ###P < 0.001 (significantly different from the NC group)
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Inhibitory effect of ULP‑SeNPs on the expression 
of inflammatory mediators in LPS primed and E.f. 
stimulated BMDMs
Concentrations of IL-6 and TNF-α were measured in 
media from macrophages primed with LPS and acti-
vated with E.f. commensal bacteria in the presence of 
ULP-SeNPs. Results showed that ULP-SeNPs (0.5  μM) 
treatment during priming and activation led to a signifi-
cant decrease in the production of both IL-6 and TNF-α 
(Fig. 7a). Furthermore, ULP-SeNPs (0.5 μM) had a strong 
effect on reducing LPS-induced mRNA levels of IL-6, 
TNF-α, iNOS and COX-2 (Fig.  7b, c). We also found 
an increased expression of COX-2 and iNOS in LPS 
primed and E.f. activated-macrophages that was mark-
edly reduced by ULP-SeNPs treatment. The densitometry 
analyses of the immunoblots is shown in Fig. 7d.
Inhibition of NF‑κB activation by ULP‑SeNPs
NF-κB regulates the expression of a large number of 
cytokines and its activation plays a role in IBD [25]. To 
determine whether ULP-SeNPs affected NF-κB activa-
tion, we measured p-p65/p-IKBα in DSS-induced colitis 
with or without ULP-SeNPs as well as in macrophages 
activated with inflammatory stimuli. Results revealed 
that ULP-SeNPs inhibited levels of p-p65/p-IKBα in 
DSS-induced colitis and macrophages activated with 
inflammatory stimuli (Fig.  8a, c). Nuclear translocation 
of NF-κB analyses in mouse colon tissues from the NC, 
DSS-treated, and DSS  +  ULP-SeNPs (0.8  ppm) groups 
revealed that ULP-SeNPs treatment caused a significant 
reduction in the level of NF-κB activation in acute colitis 
(Fig. 8b) and in LPS primed macrophages activated with 
E. faecalis (Fig. 8d). These data suggest that ULP-SeNPs 
are capable of regulating the inflammatory response by 
inhibiting NF-κB activation.
Discussion
Multiple factors contribute to the pathogenesis of IBD. 
The key role of nutrients in IBD has been observed with 
particular focus on the deleterious effects of the mod-
ern “Western diet” that increases the risk of IBD [26]. 
Micronutrients represent an ideal choice for nutritional 
intervention against IBD. Se, an essential micronutrient, 
has attracted a great deal of interest due to its important 
health effects, particularly the effects related to immune 
responses and cancer prevention activity [27]. Recent 
reviews of the role of Se in IBD have concluded that 
Se status and adequate dietary Se supply are of pivotal 
Fig. 3 Effects of ULP-SeNPs on histological manifestation in DSS-induced colitis. H&E staining images of representative colons are shown at the 
same magnification (×200) for NC (a), DSS (b), and DSS + ULP-SeNPs (c). And histological scores were evaluated (d). Each bar chart represents the 
mean ± SD (n = 10 animals for per group). **P < 0.01 (significantly different from the DSS group). ###P < 0.001 (significantly different from the NC 
group)
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importance to colonic inflammation [26, 28]. Nanopar-
ticles that include elemental Se (SeNPs) as a novel form 
of this nutrient appear to be more effective than that of 
other Se sources because of their excellent bioavailabil-
ity, biological activity, and low toxicity [29]. To address 
application of ULP-SeNPs to prevent IBD, we developed 
a stable, homogeneous formulation of ULP-SeNPs with 
consistent diameter of 130  nm. The mouse macrophage 
reporter cell line-RAW-Blue cells was used to determine 
the effects of SeNPs and ULP-SeNPs on the LPS/E.f. 
triggered NF-κB inflammatory signaling pathway. Data 
showed that ULP-SeNPs (0.5  μM) inhibited either LPS 
or E.f.-induced NF-κB hyper-activation, and did so in a 
more effective manner than ULP or SeNPs (Additional 
file 1: Figure S3). These data support the notion that ULP-
SeNPs may represent a nutriceutical with promising anti-
inflammation capacity.
In this study, we report for the first time that ULP-
SeNPs led to a reduction in the severity of the sys-
temic (e.g., BW loss and DAI scores) and local (e.g., CL 
shortened and HDS) symptoms of DSS-induced coli-
tis. Moreover, ULP-SeNPs suppressed inflammatory 
cell infiltration and local inflammation, resulting in less 
pathological damage being induced by DSS in colon. 
DSS-induced acute colitis and chronic colitis in mice 
reproduce the histological pathology of human IBD 
[30]. Optimization of dietary ULP-SeNPs supplementa-
tion might offer a promising supportive therapy for IBD 
patients as long as safety can be demonstrated. It is con-
ceivable that ULP-SeNPs would have limited side effects 
because Se nanoparticles (SeNPs) exhibit excellent bio-
availability, biological activity, and low toxicity compared 
to organic or inorganic Se. Altogether, these results indi-
cate that ULP-SeNPs might be a candidate as a potential 
therapeutic nanomedicine for prevention of IBD and 
other inflammatory diseases. However, further follow-up 
investigations of the safety and efficacy of ULP-SeNPs are 
necessary before it can be considered for the treatment of 
IBD patients.
Oxidative stress or cellular damage from free radicals, 
often involving profound lipid peroxidation are the hall-
marks of UC [31]. Mounting evidence suggests that many 
Se metabolites exhibit antioxidative properties and anti-
inflammatory roles for modulating disorders such as IBD, 
atherosclerosis, and cancer [2, 32]. In the present study, 
the results showed that ULP-SeNPs markedly increased 
the colonic GSH levels, one marker for oxidative sta-
tus, and reduced the generation of MDA to attenuate 
Fig. 4 Effects of ULP-SeNPs on immune cell infiltration into colon tissue during DSS colitis. Expression levels of CD68 (×200 magnification) were 
evaluated by immunohistochemistry in the colon tissue. Three groups including a NC, b DSS, c DSS + ULP-SeNPs and d CD68 positive cell numbers 
were counted and compared among three groups (n = 10). **P < 0.01; (significantly different from the DSS group). ###P < 0.001 (significantly differ-
ent from the NC group)
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the DSS-induced colitis in mice (Fig.  5a, b). It should 
be noted that the diets contained sufficient levels of Se 
(0.8 ppm) and the ULP-SeNPs were able to further boost 
antioxidant capacity, indicating potential benefits of 
ULP-SeNPs in boosting antioxidant capacity. The effects 
of ULP-SeNPs on systemic and local Se status and par-
ticularly on development of IBD are likely complex and 
nuanced, and our data are suggestive but not conclusive 
regarding the role of the selenoproteome in the protec-
tive actions of Se.
It is well known that the increased pro-inflammatory 
cytokines (TNF-α, IL-1β and IL-6) observed in our model 
of colitis amplify the inflammatory cascade and result in 
intestinal tissue damage in patients with UC [33]. The 
Fig. 5 Effects of ULP-SeNPs on the levels of MPO, oxidative stress and Se in DSS-induced colitis. Mice were evaluated for a MPO levels, b MDA levels, 
c GSH, and d GPx activity in colonic tissues. e Se levels in colonic tissues and f Se levels in livers were evaluated. Data represent mean ± SD (n = 10). 
*P < 0.05; (significantly different from the DSS group). #P < 0.05, ##P < 0.01,###P < 0.001 (significantly different from the NC group)
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downregulation and/or blockade of pro-inflammatory 
cytokine activity has been effective in the treatment of 
IBD [34]. Se at supranutritional levels (as inorganic sel-
enite) affects gene expression, signaling pathways, and 
cellular functions involved in inflammation However, the 
underlying mechanisms are not well understood since 
inorganic Se species and selenoproteins themselves play 
many roles within cells. In the present study, we focused 
on ULP-SeNPs that modulate gastrointestinal inflamma-
tion, which include macrophages as key regulators. We 
observed that the colonic levels of TNF-α and IL-6 in the 
DSS-induced colitis mice were markedly decreased by 
ULP-SeNPs, as measured by ELISA. The RT-PCR assay 
confirmed that the mRNA levels of these pro-inflam-
matory cytokines and the local inflammatory mediator 
MPO were reduced by ULP-SeNPs. With BMDMs stimu-
lated by LPS primed E.f.-stimulated macrophages, we 
revealed that ULP-SeNPs significantly suppressed mRNA 
levels of IL-6 and TNF-α. In addition, we demonstrated 
that ULP-SeNPs decreased the expression of iNOS and 
COX-2. NF-κB plays a central role in regulating immune 
and inflammatory processes and thus represents a key 
Fig. 6 Effects of ULP-SeNPs on inflammatory markers in DSS-induced colitis. a Levels of inflammatory cytokines including IL-6 and TNF-α were 
measured in plasma of DSS-treated mice. b Relative mRNA expressions of IL-6 and TNF-α were measured by real-time PCR. c Relative mRNA expres-
sion of iNOS and COX-2 were measured by real-time PCR. d Western blot results for iNOS and COX-2 (top) and densitometry (bottom). Each bar 
chart represents mean ± SD (n = 10 animals for each experiment). *P < 0.05; **P < 0.01; ***P < 0.001 (significantly different from the DSS group). 
##P < 0.01; ###P < 0.001 (significantly different from the NC group)
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target for developing novel treatments for inflammatory 
diseases [35]. Prior to activation, NF-κB is complexed 
with IκBα, an inhibitory protein keeping NF-κB inactive 
state in the cytoplasm. Induced by various stimuli, such 
as LPS and proinflammatory factors, NF-κB is released 
and translocates from cytoplasm into the nucleus due 
to IκBα phosphorylation, ubiquitinylation, and degrada-
tion. Phosphorylated subunit p65 plays an important role 
in triggering the transcription of certain genes. Results 
in our study showed that ULP-SeNPs strongly inhibited 
the level of NF-κB activation in colitis colon tissues and 
stimulated macrophages by suppressing the phospho-
rylation and degradation of IκBα and thus decreased 
the phosphorylation of p65. However, inflammation also 
plays a part in restoring gut homeostasis through diverse 
pathways involving the colonic macrophage family (e.g. 
M1 and M2 types), [36] and mediators such as IL-10 and 
NO. Further mechanistic studies will improve our under-
standing of the actions of ULP-SeNPs in IBD and identify 
specific mediators driving the beneficial Se effects dem-
onstrated in our studies.
The data from our in vivo and in vitro experiments sug-
gest that ULP-SeNPs might represent a modality that 
inhibits IBD. However, our study is limited by a lack of 
definitive molecules on which the increased Se acts. 
Altered redox tone in the colon and perhaps modulation 
Fig. 7 Effect of ULP-SeNPs on of inflammatory marker levels in LPS-primed E.f.-activated BMDM. a IL-6 and TNF-α levels in cell-free supernatants 
were determined by ELISA. b Relative levels of IL-6 and TNF-α mRNA were measured by real-time PCR. c Relative levels of iNOS and COX-2 mRNA 
were measured by real-time PCR. d Analyses iNOS and COX-2 protein by Western blot (top) and densitometry (bottom). Data represent mean ± SD 
(n = 3 in independent experiments). *P < 0.05; **P < 0.01; ***P < 0.001 (significantly different from the LPS group). ##P < 0.01; ###P < 0.001 (signifi-
cantly different from the control group)
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Fig. 8 Effect of ULP-SeNPs on NF-κB activation in vivo and in vitro. a Effects of ULP-SeNPs on the activation of NF-κB in colon tissues of mice with 
acute colitis and in BMDMs, as determined by immunoblotting (top) and densitometry (bottom) analysis. b NF-κB levels and nuclear translocation in 
colon tissues of mice with acute colitis. c Effects of ULP-SeNPs on the activation of NF-κB in BMDMs as analyzed by Western blot (top) and densitom-
etry (bottom) analysis. d NF-κB levels and nuclear translocation in BMDM. *P < 0.05; **P < 0.01 (significantly different from the DSS group). ##P < 0.01; 
###P < 0.001 (significantly different from the NC group). ***P < 0.001 (significantly different from the LPS group). ###P < 0.001 (significantly different 
from the control group)
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of immune cells are two ways that Se has been shown to 
affect inflammation [1]. The selenoprotein subfamilies of 
glutathione peroxidases and thioredoxin reductases may 
be involved in regulating these processes, [37] but other 
selenoproteins are likely also involved in mediating the 
effects of SeNPs. Another limitation of our data is that 
the DSS mouse model of chemically induced colitis is 
strongly macrophage driven inflammation and not com-
pletely representative of human IBD [38]. Several genetic 
models of colitis have been generated [39] and it would 
be of interest to repeat these SeNPs experiments in those 
mice.
Conclusions
The present data demonstrated that ULP-SeNPs sup-
plementation exhibits the anti-inflammatory effects to 
reduce the symptoms of acute colitis through inhibition 
the hyper activation of NF-κB in colonic tissues and mac-
rophages. Therefore, ULP-SeNPs may be a candidate for 
further evaluation as a potential therapeutic product for 
treatment IBD and other inflammatory diseases.
Methods
Materials and chemicals
DSS was obtained from MP Biomedicals (Illkirch, 
France). The glutathione (GSH), glutathione peroxidase 
(GPx) and malondialdehyde (MDA) detection kits were 
purchased from Nanjing Jiancheng Bioengineering Insti-
tute (Nanjing, China). The bicinchoninic acid (BCA) kits 
for protein assays were supplied by the Beyotime Insti-
tute of Biotechnology (Shanghai, China). Ulva lactuca 
polysaccharide was purchased from Elicityl (Grenoble, 
France). NF-κB activation assay kits were supplied by 
FIVE photon Biochemicals (San Diego, CA, USA). Dul-
becco’s modified Eagle’s medium (DMEM) and the anti-
biotic mixture (penicillin/streptomycin) were purchased 
from Invitrogen (Carlsbad, CA, USA). Proteinase inhibi-
tor cocktail and Laemmli buffer were purchased from 
Bio-Rad (Hercules, CA, USA). Antibodies purchased 
from Cell Signaling Technology (Danvers, MA, USA) 
included anti-NF-κB(p65), anti-p-p65, anti-p-IKBα, anti-
IKBα, anti-iNOS, anti-COX-2, anti-β-actin, anti-lamin 
A. Secondary antibodies for western blots were obtained 
from Li-Cor (Lincoln, Nebraska, USA). Anti-CD68 
was purchased from Santa Cruz Biotechnology (Dallas, 
Texas, USA). Hexadecyltrimethylammonium bromide, 
o-dianisidine, and lipopolysaccharide (LPS) purified from 
Escherichia coli O111:B4 were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Heat-killed Enterococcus 
faecalis (E.f.) was obtained from American Type Culture 
Collection. All of the solvents used were of high perfor-
mance liquid chromatography (HPLC) grade. Chemicals 
used were of analytical grade, including sodium selenite, 
sodium dodecyl sulfate (SDS), Tween 20, and other com-
monly used reagents were obtained from Guangdong 
Guanghua Sci-Tech (Huada & JHD, Guangzhou, China). 
The ultrapure water used in all experiments was supplied 
by a Milli-Q water purification system from Millipore 
(Bedford, MA, USA).
Preparation of ULP‑SeNPs
The solution of ULP was prepared by dissolving 1  g of 
ULP powder in 100  mL of Milli-Q water. The solution 
of 40 mM ascorbic acid was freshly prepared. As a typi-
cal procedure, varied volume of ULP solution was added 
dropwise into sodium selenite solution (1 mL, 100 mM) 
under magnetic stirring, and then 10  mL of 40  mM 
ascorbic acid solution was added into the mixture, and it 
was reconstituted to a final volume of 20 mL with Milli-Q 
water. The final concentration of Se was 5 mM, and the 
reactant concentrations of ULP were 0, 0.08, 0.16, 0.32, 
0.48 and 0.64 mg/mL. The solution was dialyzed against 
Milli-Q water until no Se was detected in the outer solu-
tion by ICP-MS analysis.
Characterization of ULP‑SeNPs
The ULP-SeNPs were characterized by microscopic and 
spectroscopic methods including transmission elec-
tron microscopy (TEM), energy dispersive X-ray (EDX), 
dynamic light scattering (DLS). Briefly, TEM was carried 
out with a Hitachi (H-7650) at an acceleration voltage of 
80 kV. The EDX were taken on a JEOL 2010 high-resolu-
tion TEM operated at 200 kV. A Zetasizer Nano ZS par-
ticle analyzer (Malvern Instruments Limited) was used 
to measure the particle size, size distribution, and stabil-
ity of the nanoparticles in aqueous solution, plasma and 
digestion fluid by DLS measurement.
Animals and induction of DSS‑induced IBD
Male C57BL/6 J mice (6–8 weeks old), SPF bedding, and 
certified diet were purchased from the Sun Yat-Sen Uni-
versity Animal Breeding Unit (Guangzhou, China). All 
animals were fed standard laboratory chow housed in 
wire cages at 21 ± 3  °C and 55 ± 15% relative humidity 
with a 12  h light/dark cycle, and allowed water ad  libi-
tum. The Se content of the diet was 0.12 ± 0.01 ppm on 
average.
Acute colitis was induced by oral administration of 
4% (w/v) DSS dissolved into drinking water, for 7  days 
according to the method employed in previous studies 
[40]. A cohort of mice was randomly divided into three 
groups (n = 10 per group) for acute treated as a normal 
control group (NC), a DSS-induced colitis group (DSS), 
and a DSS with 0.8 ppm of ULP-SeNPs treatment group 
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(DSS  +  ULP-SeNPs). Body weights (BW) were meas-
ured daily. The daily weight changes were calculated by 
percent in relation to the initial weight measured. After 
11 days, mice in each acute cohort had blood and colon 
tissues analyzed after being humanely euthanized. Blood 
was collected in a heparinized tube, immediately centri-
fuged to separate plasma, and then kept at −80  °C. The 
colon was rapidly excised and placed in 4% paraformal-
dehyde for histological assessment. The remaining colon 
samples were flash frozen and stored at −80 °C until fur-
ther analysis.
Assessment of severity of colitis
A general assessment of colitis was performed as 
described previously [41]. Briefly, the severity of the coli-
tis was measured by evaluating the disease activity index 
through the scoring of weight loss, stool consistency, 
bleeding and coat roughness (grade from 0 to 4 on sever-
ity of each index), general activity and bedding contami-
nation by stool and blood (graded from 0 to 2 on severity 
of each index).
Histological analysis
Colon tissues were collected, fixed in 4% paraformalde-
hyde, subjected to consecutive steps of alcohol–xylene 
changes, and embedded in paraffin from which 5  μm 
Sections were prepared. Standard hematoxylin and eosin 
(H&E) staining of paraffin-embedded tissue samples 
was conducted as previously described [42]. Five H&E-
stained sections from each mouse were scored blindly, as 
previously described [43]. Images were captured using a 
Zeiss Axioskop 2 plus upright light microscope and cam-
era (Zeiss, Oberkochen, Germany).
IHC staining
Parafin-embedded tissues were cut into 5  μm-thick 
sections, deparaffinized in xylene, and rehydrated in 
graded ethanol. Sections were incubated with anti-CD68 
antibodies overnight at 4  °C and then incubated with 
SignalStain®Boost IHC Detection Reagent (HRP, Rabbit) 
as indicated by the manufacturer (Cell Signaling Technol-
ogy, Danvers, MA, USA) for 30 min at room temperature. 
Finally, the sections were stained with DAB  +  Liquid 
according to manufacturer’s protocol (DAKO, Glostrup, 
Denmark).
Determination of Se
Se concentration in solutions and biological samples was 
determined by an inductively coupled plasma mass spec-
trometry (ICP-MS) method described previously [44]. To 
prepare liver and colonic tissues for this method, the tis-
sues were weighed and mineralized in HNO3 65% (ICP-
MS grade) and then diluted 100 fold in deionized water.
MPO assay
MPO activity, a marker of polymorphonuclear neutrophil 
primary granules, was measured in colonic tissues using 
the method by Bradley et al. [45]. Briefly, colon segments 
were homogenized at 50  mg/mL in phosphate buffer 
(50  mmol/L, pH 6.0) with 0.5% hexadecyltrimethylam-
monium bromide. Samples were centrifuged at 30,000×g 
for 15 min at 4 °C after freezing and thawing 3 times. The 
supernatants were diluted 1/30 with 50  mmol/L phos-
phate buffer (pH 6.0) containing 0.167  mg/mL o-diani-
sine (Sigma) and 0.0005% H2O2. Changes in absorbance 
between 1 and 3  min at 450  nm were measured with a 
spectrophotometer. MPO was expressed in units per mil-
ligram of wet tissue.
Glutathione content, GPx activity and lipid peroxidation 
assay
Colon tissue (100 mg) was washed and homogenized in 
cooled PBS. The samples were then homogenized fol-
lowed by centrifugation at 3000 rpm for 15 min. Super-
natant was collected for measuring total GSH, GPx 
activity, and lipid peroxidation of MDA using GSH, GPx 
and MDA detection kits, respectively. All assays were 
conducted according to the manufacturer’s instructions. 
The protein content was assayed by bicinchoninic acid 
(BCA) kits.
Cell culture
Bone marrow-derived macrophages (BMDMs) were pre-
pared as previously described [46]. On day 5 of culture, 
BMDMs were plated at a density of 2 × 106 cells/well in 
six well plates in 2 mL DMEM with 5% FBS (Life Tech-
nologies, Gaithersburg, MD) penicillin (100 U/mL), and 
streptomycin (50 U/mL) overnight at 37 °C in a humidi-
fied incubator with a 5% CO2 atmosphere. The next day, 
cultured cells were pretreated with ULP-SeNPs at the 
indicated concentrations for 1  h and then were primed 
for 18  h with LPS (100  ng/mL), followed by 1  h stimu-
lation with E. f. (1 μg/mL). Supernatants of the cultures 
were collected at the indicated time point for cytokine 
detection.
RNA isolation, cDNA synthesis, and real‑time PCR
To detect the effect of ULP-SeNPs on gene expression in 
colon tissues and LPS primed and E.f.-stimulated cells, Tis-
sue samples were thawed and RNA extracted using RNeasy 
Mini kit and RNase-free DNase I (Qiagen, Hilden, Germany), 
in accordance with the manufacturer’s instructions. BMDMs 
were preincubated on six-well plates (1 ×  106  cell/mL) and 
were pretreated with ULP-SeNPs (0.5 μM) 1 h prior to LPS 
(100 ng/mL) primed and E. f. (1 μg/mL) treatment in a 37 °C, 
5% CO2 incubator for 12 h. Total RNA from BMDMs was per-
formed using RNeasy (Qiagen, Hilden, Germany) according 
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to the manufacturer’s instructions. The quantity and quality 
of RNA were determined by Nano Drop ND-1000 (Thermo 
Scientific, Waltham, MA, USA). The cDNA was synthesized 
using Superscript III (Invitrogen, Carlsbad, CA, USA) and 
oligo dT primer, with 2 µg of total RNA per 50 µL reaction. 
For real-time PCR, 1  µL of this cDNA was used in 10  µL 
reactions with Platinum SYBR Green qPCR SuperMix-
UDG (Invitrogen). Reactions were carried out in a 9700HT 
thermal cycler (Applied Biosystems, Foster City, CA) using 
the following conditions: denaturation for 2  min at 50  °C, 
for 2 min at 95  °C, and 40 cycles of 95  °C at 15  s, 60  °C at 
60  s. The mouse primers used were as follows: IL-6 (for-
ward: 5′-AGAAGGAGTGGCTAAGGACCAA-3′; reverse: 
5′-ACGCACTAGGTTTGCCGAGTA-3′), β-actin (forward: 
5′-GCATTGTTACCAACTGGGACGA-3′; reverse: 5′-TGGCTGG 
GGTGTTGAAGGTC-3′), TNF-α forward: (5′-AGGACCCA 
GTGGTGGGAAGCT-3′; reverse: 5′-AAAGAGGAGGCAA 
GGTAGAGA-3′), IL-10 (forward: 5′-GCTCTTACTGACTGG 
CATGAG-3′; reverse: 5′-CGCAGCTCTAGGAGCATGT 
G-3′), COX-2 (forward: 5′-TTGCTGTACAAGCAGTGGCA 
AAGG-3′; reverse: 5′-AGGACAAACACCGGAGGGAATCT 
T-3′), iNOS (forward: 5′-CAGATCGAGCCCTGGAAG 
AC-3′; reverse: 5′-CTGGTCCATGCAGACAACCT-3′). Rela-
tive gene expression was calculated according to the 2−Ct 
method [47] using mouse β-actin as an endogenous control 
for normalization. Results were expressed as fold changes rela-
tive to the negative control samples.
Enzyme‑linked immunosorbent assay
Plasma samples and cell supernatants were analyzed for 
levels of inflammatory cytokines including TNF-a, IL-6 
and IL-10 using commercially available enzyme-linked 
immunosorbent assay (ELISA) kits (R&D Systems Inc, 
USA), according to the manufacturer’s instructions.
Western blot analysis
Cells pellets were harvested and lysed in lysis buffer 
[150  mM NaCl, 5  mM EDTA, 50  mM Tris–HCl (pH 
7.4), 1% Triton X-100, and 0.5% sodium deoxycholate] 
with a 1× proteinase inhibitor cocktail. Colon tissues 
were homogenized with lysis buffer on ice and then cen-
trifuged at 13,000×g for 15  min at 4  °C. In some cases, 
nuclear and cytosolic fractions were separated from cells 
or colon tissues using the NF-κB activation assay kits. 
After separation on a 12% polyacrylamide gel, proteins 
were transferred to polyvinylidene difluoride (PVDF) 
membranes (Millipore) and then incubated using spe-
cific antibodies to detect target proteins. After the pri-
mary antibody reaction overnight at 4  °C, the PVDF 
membrane was washed three times with TBST (137 mM 
NaCl, 2.7 mM KCl, 19 mM Tris base, and 0.1% Tween 20) 
and incubated with secondary Abs from Li-Cor for 1 h. 
Membranes were washed with TBST, and signals were 
detected with densitometry conducted using the Odys-
sey imaging system (Li-Cor, Lincoln, NE). Densitometry 
of blots was analyzed and normalized by β-actin or lamin 
A using ImageJ (National Institutes of Health, Bethesda, 
MD).
Statistical analysis
All comparison analyses were conducted using the SPSS 
statistical software package (SPSS 13.0 for Windows, SPSS, 
Inc., Chicago, IL). A P value of <0.05 was considered sta-
tistically significant. Comparison of mean values was done 
using analysis of variance (ANOVA). For the body weight 
change, DAI scores and colon lengths were analyzed using 
one-way ANOVA (Welch ANOVA in cases of unequal 
variance) followed by the Games–Howell post hoc test. 
All other analyses of equal sample sizes for each group and 
equal variances among the groups were compared using 
one-way ANOVA with the Tukey post hoc test.
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